Compugen Ltd (CGEN) showcases promising clinical progress and a strong cash position, despite facing revenue and net loss hurdles in Q1 2026.

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present ...

View Compugen Ltd. CGEN stock quote prices, financial information, real-time forecasts, and company news from CNN.

Compugen (CGEN) is maintained at a Buy rating, driven by advancing clinical programs and upcoming catalysts in oncology.

COM503 a potential first-in-class, high affinity anti- IL18 binding protein antibody frees endogenous IL-18 to inhibit cancer growth Compugen plans to file COM503 IND in 2024 "We are very excited to ...

HOLON, Israel, July 21, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered ...

HOLON, Israel, July 19, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first ...

Compugen (CGEN) is scheduled to announce Q1 earnings results on Monday, May 18th, after market close. The consensus EPS Estimate is -$0.08 (flat Y/Y) and the consensus Revenue Estimate is $1.26M (-45.

Compugen (CGEN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.08 per share a year ago. These figures are ...

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will ...

The stock rose as high as 18.5% before falling a bit toward the close. Compugen may have benefitted from a turn toward growth stocks on Thursday in the markets. The company focuses on oncology ...